Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 2
2016 1
2018 3
2019 2
2020 3
2021 2
2022 1
2023 3
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

15 results

Results by year

Filters applied: . Clear all
Page 1
Systematic vitamin D supplementation is associated with improved outcomes and reduced thyroid adverse events in patients with cancer treated with immune checkpoint inhibitors: results from the prospective PROVIDENCE study.
Bersanelli M, Cortellini A, Leonetti A, Parisi A, Tiseo M, Bordi P, Michiara M, Bui S, Cosenza A, Ferri L, Giudice GC, Testi I, Rapacchi E, Camisa R, Vincenzi B, Caruso G, Rauti AN, Arturi F, Tucci M, Santo V, Ricozzi V, Burtet V, Sgargi P, Todeschini R, Zustovich F, Stucci LS, Santini D, Buti S. Bersanelli M, et al. Among authors: rapacchi e. Cancer Immunol Immunother. 2023 Nov;72(11):3707-3716. doi: 10.1007/s00262-023-03522-3. Epub 2023 Aug 28. Cancer Immunol Immunother. 2023. PMID: 37638980 Free PMC article.
Thirty-day mortality in hospitalised patients with lung cancer: incidence and predictors.
Leonetti A, Peroni M, Agnetti V, Pratticò F, Manini M, Acunzo A, Marverti F, Sulas S, Rapacchi E, Mazzaschi G, Perrone F, Bordi P, Buti S, Tiseo M. Leonetti A, et al. Among authors: rapacchi e. BMJ Support Palliat Care. 2023 Sep 4:spcare-2023-004558. doi: 10.1136/spcare-2023-004558. Online ahead of print. BMJ Support Palliat Care. 2023. PMID: 37666650
PD-L1 SNPs as biomarkers to define benefit in patients with advanced NSCLC treated with immune checkpoint inhibitors.
Minari R, Bonatti F, Mazzaschi G, Dodi A, Facchinetti F, Gelsomino F, Cinquegrani G, Squadrilli A, Bordi P, Buti S, Bersanelli M, Leonetti A, Cosenza A, Ferri L, Rapacchi E, Quaini F, Ardizzoni A, Tiseo M. Minari R, et al. Among authors: rapacchi e. Tumori. 2022 Feb;108(1):47-55. doi: 10.1177/03008916211014954. Epub 2021 May 18. Tumori. 2022. PMID: 34002648
Clinical and hematologic parameters address the outcomes of non-small-cell lung cancer patients treated with nivolumab.
Facchinetti F, Veneziani M, Buti S, Gelsomino F, Squadrilli A, Bordi P, Bersanelli M, Cosenza A, Ferri L, Rapacchi E, Mazzaschi G, Leonardi F, Quaini F, Ardizzoni A, Missale G, Tiseo M. Facchinetti F, et al. Among authors: rapacchi e. Immunotherapy. 2018 Jun;10(8):681-694. doi: 10.2217/imt-2017-0175. Immunotherapy. 2018. PMID: 29882691
Immune context characterization and heterogeneity in primary tumors and pulmonary metastases from renal cell carcinoma.
Bersanelli M, Gnetti L, Varotti E, Ampollini L, Carbognani P, Leonardi F, Rusca M, Campanini N, Ziglioli F, Dadomo CI, Pilato FP, Cortellini A, Rapacchi E, Caruso G, Silini EM, Maestroni U, Buti S. Bersanelli M, et al. Among authors: rapacchi e. Immunotherapy. 2019 Jan;11(1):21-35. doi: 10.2217/imt-2018-0097. Immunotherapy. 2019. PMID: 30702014 Free article.
INfluenza Vaccine Indication During therapy with Immune checkpoint inhibitors: a transversal challenge. The INVIDIa study.
Bersanelli M, Giannarelli D, Castrignanò P, Fornarini G, Panni S, Mazzoni F, Tiseo M, Rossetti S, Gambale E, Rossi E, Papa A, Cortellini A, Lolli C, Ratta R, Michiara M, Milella M, De Luca E, Sorarù M, Mucciarini C, Atzori F, Banna GL, La Torre L, Vitale MG, Massari F, Rebuzzi SE, Facchini G, Schinzari G, Tomao S, Bui S, Vaccaro V, Procopio G, De Giorgi U, Santoni M, Ficorella C, Sabbatini R, Maestri A, Natoli C, De Tursi M, Di Maio M, Rapacchi E, Pireddu A, Sava T, Lipari H, Comito F, Verzoni E, Leonardi F, Buti S. Bersanelli M, et al. Among authors: rapacchi e. Immunotherapy. 2018 Oct;10(14):1229-1239. doi: 10.2217/imt-2018-0080. Immunotherapy. 2018. PMID: 30326787 Free article.
Clinical impact of COVID-19 in a single-center cohort of a prospective study in cancer patients receiving immunotherapy.
Bersanelli M, Zielli T, Perrone F, Casartelli C, Pratticò F, Rapacchi E, Camisa R, Tognetto M, Clemente A, Giannarelli D, Rebuzzi SE, Leonetti A, Bordi P, Tiseo M, Buti S. Bersanelli M, et al. Among authors: rapacchi e. Immunotherapy. 2020 Oct;12(15):1139-1148. doi: 10.2217/imt-2020-0211. Epub 2020 Sep 15. Immunotherapy. 2020. PMID: 32933369 Free PMC article.
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study.
Bersanelli M, Buti S, Giannarelli D, Leonetti A, Cortellini A, Russo GL, Signorelli D, Toschi L, Milella M, Pilotto S, Bria E, Proto C, Marinello A, Randon G, Rossi S, Vita E, Sartori G, D'Argento E, Qako E, Giaiacopi E, Ghilardi L, Bettini AC, Rapacchi E, Mazzoni F, Lavacchi D, Scotti V, Ciccone LP, De Tursi M, Di Marino P, Santini D, Russano M, Bordi P, Di Maio M, Audisio M, Filetti M, Giusti R, Berardi R, Fiordoliva I, Cerea G, Pizzutilo EG, Bearz A, De Carlo E, Cecere F, Renna D, Camisa R, Caruso G, Ficorella C, Banna GL, Cortinovis D, Brighenti M, Garassino MC, Tiseo M. Bersanelli M, et al. Among authors: rapacchi e. Lung Cancer. 2020 Dec;150:123-131. doi: 10.1016/j.lungcan.2020.10.008. Epub 2020 Oct 22. Lung Cancer. 2020. PMID: 33130353 Free article.
Retrospective immunophenotypical evaluation of MET, PD-1/PD-L1, and mTOR pathways in primary tumors and pulmonary metastases of renal cell carcinoma: the RIVELATOR study addresses the issue of biomarkers heterogeneity.
Bersanelli M, Gnetti L, Pilato FP, Varotti E, Quaini F, Campanini N, Rapacchi E, Camisa R, Carbognani P, Silini EM, Rusca M, Leonardi F, Maestroni U, Rizzo M, Brunelli M, Buti S, Ampollini L. Bersanelli M, et al. Among authors: rapacchi e. Explor Target Antitumor Ther. 2023;4(4):743-756. doi: 10.37349/etat.2023.00165. Epub 2023 Aug 31. Explor Target Antitumor Ther. 2023. PMID: 37720351 Free PMC article.
From the beginning to resistance: Study of plasma monitoring and resistance mechanisms in a cohort of patients treated with osimertinib for advanced T790M-positive NSCLC.
Bordi P, Del Re M, Minari R, Rofi E, Buti S, Restante G, Squadrilli A, Crucitta S, Casartelli C, Gnetti L, Azzoni C, Bottarelli L, Petrini I, Cosenza A, Ferri L, Rapacchi E, Danesi R, Tiseo M. Bordi P, et al. Among authors: rapacchi e. Lung Cancer. 2019 May;131:78-85. doi: 10.1016/j.lungcan.2019.03.017. Epub 2019 Mar 19. Lung Cancer. 2019. PMID: 31027702 Clinical Trial.
15 results